Your session is about to expire
← Back to Search
Aspheric IOL
Clareon Vivity/Vivity Toric Extended Vision for Aphakia
N/A
Waitlist Available
Research Sponsored by Alcon Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up visit 1 (day 1-14)
Awards & highlights
Study Summary
This trial looks at how well different eye lenses work for people who have already had them implanted. It will measure how well they perform against key goals.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ visit 1 (day 1-14)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~visit 1 (day 1-14)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mean Binocular photopic BCDVA (logMAR) at 4 m
Mean Binocular photopic DCIVA (logMAR) at 66 cm
Secondary outcome measures
Mean Binocular photopic DCNVA (logMAR) at 40 cm
Proportion of subjects who respond "Never" to Question 1 of the spectacle use questionnaire (IOLSAT)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Clareon Vivity/Vivity Toric Extended VisionExperimental Treatment1 Intervention
Previous implantation, defined as 90-180 days post second eye implantation, with Clareon Vivity/Vivity Toric Extended Vision IOL (intraocular lens)
Group II: Clareon/Clareon Toric AsphericActive Control1 Intervention
Previous implantation, defined as 90-180 days post second eye implantation, with Clareon/Clareon Toric Aspheric IOL (intraocular lens)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clareon Vivity/Vivity Toric Extended Vision IOL
2023
N/A
~160
Find a Location
Who is running the clinical trial?
Alcon ResearchLead Sponsor
703 Previous Clinical Trials
124,316 Total Patients Enrolled
16 Trials studying Aphakia
5,722 Patients Enrolled for Aphakia
Clinical Trial Lead, Surgical CRDStudy DirectorAlcon Research, LLC
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have eye problems that could affect the success of surgery, according to the doctor's expert opinion.You have a condition called PCO that is affecting your vision in a significant way.There may be additional reasons why you may not be able to participate in the study, as determined by the study's specific guidelines.There may be additional requirements that need to be met as specified in the study's rules.
Research Study Groups:
This trial has the following groups:- Group 1: Clareon/Clareon Toric Aspheric
- Group 2: Clareon Vivity/Vivity Toric Extended Vision
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is it possible to enlist in the trial at this juncture?
"Based on clinicaltrials.gov's records, this trial is presently not recruiting patients; although it was initially posted and later updated in May of 2023. Despite this, there are 9 additional trials actively enrolling at the moment."
Answered by AI
In how many distinct facilities is this research being administered?
"For this particular trial, potential patients can enrol at Eye Center of Northern Colorado, PC in Fort Collins, Grosinger, Spigelman & Grey Eye Surgeons P.C. in Bloomfield Hills as well as Associated Eye Care based out of Stillwater and 7 other sites."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger